Stage 1A endometrial cancer is cancer caught early, while it is still confined to the uterus, and it is among the most curable cancers there are. For most women, surgery to remove the uterus is the whole treatment, and life expectancy ends up close to that of women who never had cancer.1Cancer. Carcinoma of the endometrium: Effect of stage and grade on survival Stage 1A is not one single outlook, though. What the tumor looks like under the microscope can matter as much as the stage itself.
Survival Rates for Stage 1A Endometrial Cancer
On a pathology report, stage 1A means the cancer is in the uterine lining or has grown less than halfway into the myometrium, the muscle wall of the uterus. Newer staging from 2023 splits 1A further. Stage 1A1 means the cancer is in a polyp or the lining only. Stage 1A2 means it is less than halfway into the wall, without vessel spread. Stage 1A3 means low-grade cancer in the uterus and an ovary, not breaking through the ovary’s surface.2PubMed Central. Endometrial Cancer: 2023 Revised FIGO Staging System and the Role of Imaging Your report may show one of these newer labels, and the lower sub-stages generally carry the best outlook.
The stage on your report comes from the surgeon’s findings and the pathologist’s measurements after the uterus is examined, so it is usually not final until a week or two after surgery. Older reports and many survival charts use plain 1A, while a newer report may show 1A1, 1A2 or 1A3. The same cancer can be labeled differently depending on when and where it was staged. If your report only says stage 1A and you want the newer label, ask whether the pathologist can say which sub-stage applies.
In a nationwide group of women with stage 1A, about 89 in 100 were alive after five years.3PubMed. Survival after stage IA endometrial cancer; can follow-up be altered? A prospective nationwide Danish survey But about 97 in 100 had not died of endometrial cancer at five years.4PubMed. Survival after stage IA endometrial cancer; can follow-up be altered? A prospective nationwide Danish survey The gap between those two numbers is mostly deaths from other causes, since many women diagnosed are older or have other health conditions.
Overall survival counts deaths from any cause; cancer-specific survival counts only deaths from endometrial cancer, and for stage 1A it is the number that describes the cancer’s threat. Your doctor may quote either one, so ask which they mean.
For the lowest-risk form, stage 1A grade 1, five-year survival was about 92 in 100.5PubMed Central. Recurrence risk factors in stage IA grade 1 endometrial cancer Women with low-grade stage 1 disease lived about as long as women of the same age without cancer, even 15 years out.6Cancer. Carcinoma of the endometrium: Effect of stage and grade on survival By comparison, five-year survival for all stage 1 cases was about 95 in 100, versus about 49 in 100 at stage 3.7PubMed Central. The effect of myometrial invasion on prognostic factors and survival analysis in endometrial carcinoma
All of these figures are averages, not predictions. They come from women treated years ago, before newer tests and staging, and they mix younger and older women and different tumor types. Your own report details, covered below, shift your odds up or down.
How Likely Is Stage 1A Cancer to Come Back
About 4 in 100 women with stage 1A had a recurrence in a nationwide follow-up.8PubMed. Survival after stage IA endometrial cancer; can follow-up be altered? A prospective nationwide Danish survey In stage 1A grade 1 cancer, about 8 in 100 recurred.9PubMed Central. Recurrence risk factors in stage IA grade 1 endometrial cancer The risk is not the same for every woman with stage 1A, though, and the report details described in the next section decide whether you sit below or above that average.
Recurrence does matter when it happens. Women whose cancer recurred had much lower five-year survival, about 60 in 100 versus 95 in 100.10PubMed Central. Recurrence risk factors in stage IA grade 1 endometrial cancer That gap is why doctors still plan follow-up: a recurrence caught while it is local is far more treatable than one found late.
About two-thirds of stage 1A recurrences were in the vagina.11PubMed. Survival after stage IA endometrial cancer; can follow-up be altered? A prospective nationwide Danish survey Vaginal-only recurrences carry a far better outlook, with women living a median of about 14 years after recurrence.12PubMed. Recurrent early stage endometrial cancer: Patterns of recurrence and results of salvage therapy Recurrences in the pelvis or distant organs had median survival of only about 1 year.13PubMed. Recurrent early stage endometrial cancer: Patterns of recurrence and results of salvage therapy Radiation treatment for a vaginal recurrence was linked to longer survival,14PubMed. Recurrent early stage endometrial cancer: Patterns of recurrence and results of salvage therapy and in early-stage cancer, surgery, radiation or chemotherapy for a pelvic recurrence each improved survival.15PubMed. Recurrent early stage endometrial cancer: Patterns of recurrence and results of salvage therapy
A vaginal recurrence often shows up as new bleeding or discharge from the vagina, and your doctor may feel it during a pelvic exam. Because it is local, radiation can often cure it. Most recurrences appear within the first few years after surgery, which is why follow-up visits are most frequent early on.
Report Details That Raise or Lower Your Risk
Most stage 1A cancers are endometrioid, the common type. Grade describes how abnormal the cells look, from 1 (closest to normal) to 3. About 92 in 100 stage 1A cancers have low-risk features.16PubMed. Survival after stage IA endometrial cancer; can follow-up be altered? A prospective nationwide Danish survey Endometrioid cancers are usually driven by estrogen exposure and tend to grow slowly, and grade 1 tumors carry the most favorable outlook.
Serous and clear cell cancers behave differently and are more likely to spread beyond the uterus, so doctors treat the type itself as a reason for closer review even when the tumor is small. Still, these more aggressive types did about as well at stage 1 as grade 3 endometrioid cancer, better than often assumed.17PubMed. Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium
Your report may also say LVSI (lymphovascular space invasion), meaning cancer cells were seen inside small blood or lymph vessels near the tumor. In stage 1A grade 1 or 2 endometrioid cancer, about 14 in 100 with LVSI recurred, versus about 5 in 100 without it.18PubMed Central. Evaluation of prognostic significance of lymphovascular space invasion in early stage endometrial cancer: a systematic review and meta-analysis In early low-grade cancer, five-year survival was about 79 in 100 with LVSI versus 92 in 100 without.19PubMed Central. The impact of lymphovascular space invasion on survival in early stage low-grade endometrioid endometrial cancer Recurrences linked to LVSI were mostly distant rather than in the vagina.20PubMed Central. The Impact of Lymphovascular Space Invasion on Recurrence and Survival in FIGO Stage I Node-Negative Endometrioid Endometrial Cancer That makes LVSI one of the main reasons doctors suggest added treatment.
When you read your report, look for the histologic type, grade, depth of invasion, and LVSI. Depth is often given as a percentage of the muscle wall, and LVSI may be described as absent, focal or substantial. Ask for a copy and go through it with your oncologist.
Lymph nodes are part of the picture too. Many women have sentinel lymph nodes removed during surgery. Finding cancer in them would move the stage beyond 1A, so negative nodes support the stage 1A outlook. Even among low-risk patients, node spread turns up now and then, in about 10 in 100 in one review.
Molecular Groups and Your Outlook
Many labs now test tumors and sort them into molecular groups. Tumors fall into four: p53abn (p53-abnormal), POLE-mutated, mismatch repair-deficient, and a group with no specific molecular profile. In stage 1, POLE-mutated tumors had the best outcomes and p53-abnormal ones the worst.21PubMed Central. Prognosis of Stage I Endometrial Cancer According to the FIGO 2023 Classification Taking into Account Molecular Changes Mismatch repair-deficient and no-specific-profile tumors fall in the middle.
Among high-grade stage 1 tumors, POLE-mutated cases had about a quarter of the recurrence risk of others.22PubMed Central. The TCGA Molecular Classification of Endometrial Cancer and Its Possible Impact on Adjuvant Treatment Decisions At the other end, in stage 1A p53-abnormal cancer, about 16 in 100 recurred even without invasion into the muscle wall.23PubMed. Recurrence rates and patterns of recurrence in stage IA p53abn endometrial cancer with and without myometrial invasion Those recurrences were mostly distant, and with chemotherapy the risk fell to about 8 in 100.24PubMed. Recurrence rates and patterns of recurrence in stage IA p53abn endometrial cancer with and without myometrial invasion
It is worth asking whether your tumor was tested and which group it fell into. A POLE result can mean less treatment is needed, while a p53-abnormal result often leads to a discussion about chemotherapy.
Do You Need Treatment After Surgery
Women with stage 1A grade 1 or 2 endometrioid cancer gained no survival benefit from external or vaginal radiation.25PubMed. Impact of vaginal brachytherapy on survival in stage I endometrioid endometrial carcinoma Vaginal brachytherapy is radiation placed inside the vagina, and it has not been shown to lengthen survival in any group.26Gynecologic Oncology. Is vaginal brachytherapy necessary in patients with early stage, high risk endometrial cancer? It does lower vaginal recurrence, to about 2 to 3 in 100.27Gynecologic Oncology. Is vaginal brachytherapy necessary in patients with early stage, high risk endometrial cancer? In stage 1A endometrioid cancer, chemotherapy did not improve survival even when cancer cells were found in abdominal fluid at surgery.28PubMed Central. Prognosis and adjuvant chemotherapy for patients with positive peritoneal cytology in stage IA endometrial cancer
Treatment after surgery is chosen by the risk of recurrence, not by stage alone, so two women with stage 1A may be told different things. Doctors group tumors into low, intermediate and high risk using grade, type, depth, LVSI and molecular group. Observation alone is the standard for the low-risk group, and that is a recommendation based on evidence, not a sign that care is being withheld. Added treatment comes up with high grade, serous or clear cell types, substantial LVSI, or p53-abnormal molecular results.
Internal vaginal radiation can cause vaginal dryness and narrowing, and it takes several short clinic sessions. Skipping it often means watching closely instead.
Your Health Beyond the Cancer
In early endometrial cancer, women with a BMI of 40 or higher had lower survival than those under 30.29PubMed. Treatment effects, disease recurrence, and survival in obese women with early endometrial carcinoma: a Gynecologic Oncology Group study But two-thirds of deaths in that group were from non-cancer causes.30PubMed. Treatment effects, disease recurrence, and survival in obese women with early endometrial carcinoma: a Gynecologic Oncology Group study Another study found no survival difference by BMI after adjusting for other factors.31European Journal of Gynaecological Oncology. Treatment outcomes and survival in morbidly obese women with endometrial cancer Excess weight is a major cause of endometrial cancer in the first place, so many women diagnosed carry related conditions such as high blood pressure and diabetes. Managing heart health, diabetes and weight is therefore part of living well after this cancer. A survivorship plan can be simple: regular checkups with your primary care doctor, checks of blood pressure, blood sugar and cholesterol, and staying active, which helps both heart and mood.
Outcomes are also unequal. Among young women with early-stage cancer, Black women were about 24% more likely to die than white women.32PubMed Central. Racial Disparities in Young Women with Endometrial Cancer Black and Hispanic patients were less likely to receive recommended treatment, though this explained only a small part of the gap.33Cancer Epidemiology, Biomarkers & Prevention. Racial and ethnic disparities in endometrial cancer survival: The mediating role of guideline-concordant treatment Asking whether your care follows current guidelines is reasonable.
Keeping Ovaries or Fertility
In women under 50 with stage 1 grade 1 cancer, keeping the ovaries did not raise cancer deaths.34PubMed Central. Ovarian Conservation and Overall Survival in Young Women With Early-Stage Low-Grade Endometrial Cancer Those who kept their ovaries had better overall survival and fewer heart-related deaths.35PubMed Central. Ovarian Conservation and Overall Survival in Young Women With Early-Stage Low-Grade Endometrial Cancer For stage 1 grade 2 and 3 endometrioid cancer, keeping ovaries did not worsen survival either.36PubMed. Safety of ovarian preservation for premenopausal patients with FIGO stage I grade 2 and 3 endometrioid endometrial adenocarcinoma
Ovaries produce hormones that protect bones and the heart. Removing them before the natural age of menopause causes sudden menopause, with hot flashes and sleep problems. The decision depends on the tumor’s features and on any family history of ovarian or breast cancer, so it is individualized.
Some women with grade 1 disease confined to the lining use hormone (progestin) treatment instead of hysterectomy. About 77 in 100 go into remission.37PubMed. The oncological and reproductive outcomes of fertility-preserving treatments for stage 1 grade 1 endometrial carcinoma: a systematic review and meta-analysis But about 20 in 100 relapse, and about 20 in 100 have a live birth.38PubMed. The oncological and reproductive outcomes of fertility-preserving treatments for stage 1 grade 1 endometrial carcinoma: a systematic review and meta-analysis A BMI of 25 or higher made a complete response less likely.39PubMed Central. Fertility-sparing treatment in early endometrial cancer: current state and future strategies
Treatment means daily hormone pills or a hormone IUD, repeat biopsies every few months, and surgery if the cancer doesn’t respond. It is usually done at specialist centers. Most women are advised to have the uterus removed once childbearing is complete.
Follow-Up and Warning Signs
Knowing the warning symptoms, plus a regular history and exam, catches most recurrences.40American Journal of Obstetrics & Gynecology. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations Routine scans and Pap-type tests haven’t been shown to find recurrence early enough to change outcomes.41American Journal of Obstetrics & Gynecology. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations Pelvic and rectal examination is the check shown to be useful.42PubMed. Surveillance procedures for patients treated for endometrial cancer: a review of the literature
A typical schedule is a visit every 3 to 6 months for the first two to three years, then every 6 to 12 months up to five years. Higher-risk tumors may be seen more often.
Report any vaginal bleeding or bloody discharge, pelvic or abdominal pain or swelling, or a persistent cough, weight loss or leg swelling. Don’t wait for the next visit.
Recovery is emotional as well. Long-term survivors reported anxiety or depression about twice as often as the general population.43PubMed Central. Long-term quality of life outcomes of women treated for early-stage endometrial cancer Raising mood or worry with your care team is worthwhile.